Zituvimet Tablet, Film Coated
Product Images NDC 70710-1786

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Zituvimet (NDC 70710-1786). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals (usa) Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (A33d6fab 1e72 4153 9f24 8a781e838f94 01)

Chemical structure of Sitagliptin, an active ingredient in ZITUVIMET, showing its molecular composition with trifluoromethyl and fluorophenyl functional groups.*

FDA Label Image

Structure (A33d6fab 1e72 4153 9f24 8a781e838f94 02)

Chemical structure of Sitagliptin Hydrochloride, shown with molecular groups including methyl, amine, and hydrazine attached to a central pyrrolopyrimidine core, displayed with its hydrochloride salt form.*

FDA Label Image

Graph (A33d6fab 1e72 4153 9f24 8a781e838f94 03)

Line chart depicting the least squares mean change from baseline over 24 weeks for different treatments including placebo, sitagliptin 100 mg once daily, metformin 1000 mg twice daily, and two combination regimens of sitagliptin 50 mg plus metformin 500 mg or 1000 mg twice daily. The x-axis represents time in weeks; the y-axis shows change from baseline.*

FDA Label Image

Graph (A33d6fab 1e72 4153 9f24 8a781e838f94 04)

A line graph comparing the least squares mean change from baseline over 52 weeks between Sitagliptin 100 mg and Glipizide treatments. The x-axis represents time in weeks, and the y-axis shows the mean change values from 0 to approximately -1.5. Both treatments show similar trends in decreasing mean values, stabilizing after about 18 weeks, and gradually increasing toward week 52.*

FDA Label Image

Label (A33d6fab 1e72 4153 9f24 8a781e838f94 05)

Zituvimet 50 mg/500 mg film-coated tablets packaging label containing sitagliptin and metformin hydrochloride as active ingredients. The label states the dosage form as oral tablets, includes the NDC 70710-1786-6, and indicates a quantity of 60 tablets per container. The labeler is Zydus Pharmaceuticals (USA) Inc., with manufacturing by Zydus Lifesciences Ltd., India. The label features usage instructions to dispense the enclosed medication guide and storage information.*

FDA Label Image

Label (A33d6fab 1e72 4153 9f24 8a781e838f94 06)

Zituvimet 50 mg/1,000 mg tablets packaging label showing a film-coated oral tablet of sitagliptin and metformin hydrochloride. The label includes NDC 70710-1787-6, indicates a count of 60 tablets, and is manufactured by Zydus Pharmaceuticals (USA) Inc. It provides storage instructions, child safety information, and distributor details for Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.